- Home
- VTGN vs VYNE Comparison
VTGN vs VYNE Comparison
Compare VTGN & VYNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VTGN | VYNE |
|---|---|---|
| Founded | 1998 | 2003 |
| Country | United States | United States |
| Employees | N/A | 10 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.8M | 20.4M |
| IPO Year | 2014 | 2017 |
Fundamental Metrics
Financial Performance| Metric | VTGN | VYNE |
|---|---|---|
| Price | $0.56 | $0.61 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 1 |
| Target Price | ★ $0.90 | N/A |
| AVG Volume (30 Days) | ★ 422.3K | 172.4K |
| Earning Date | 02-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ N/A |
| Revenue This Year | $124.49 | N/A |
| Revenue Next Year | $353.99 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.43 | $0.29 |
| 52 Week High | $5.14 | $1.98 |
Technical Indicators
Market Signals| Indicator | VTGN | VYNE |
|---|---|---|
| Relative Strength Index (RSI) | 43.65 | 52.32 |
| Support Level | $0.50 | $0.56 |
| Resistance Level | $0.66 | $0.75 |
| Average True Range (ATR) | 0.04 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 34.57 | 56.41 |
Price Performance
Historical ComparisonAbout VTGN VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.
About VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary and differentiated therapies for the treatment of immuno-inflammatory conditions. The company is also in the pre-clinical stages of research, develop and commercialize products containing small molecule bromodomain and extra-terminal domain (BET) inhibitors for the treatment of any disease, disorder or condition in human. Its products include AMZEEQ, ZILXI, and FCD105.